Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 230-072-0 | CAS number: 6938-94-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- Data is from study report
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Principles of method if other than guideline:
- Repeated dose oral toxicity study was conducted to determine the toxic nature of the test chemical upon repeated oral administration for 28 days
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- Diisopropyl adipate
- EC Number:
- 230-072-0
- EC Name:
- Diisopropyl adipate
- Cas Number:
- 6938-94-9
- Molecular formula:
- C12H22O4
- IUPAC Name:
- 1,6-bis(propan-2-yl) hexanedioate
- Reference substance name:
- Di isopropyl adipate
- IUPAC Name:
- Di isopropyl adipate
- Details on test material:
- -Name of the test material : Diisopropyl adipate
- Molecular formula (if other than submission substance): C12H22O4
- Molecular weight (if other than submission substance): 230.30 g/mol
- Substance type: Organic
-Physical state : liquid
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Animals were in-bred at sa-FORD Animal facility.
- Age at study initiation: 6-7 weeks at the start of treatment
- Weight at study initiation: Males: 159-191 g and Females: 139-156 g
- Fasting period before study:
- Housing: A total 2-3 rats/sex were housed in Polycarbonate cages (size 37 [cm] x 21 [cm], height 20 [cm]). Cage rotation was carried out weekly.
Sterilized corn cob produced from pure corn, dried and free from dust, was used as bedding material. It was renewed as often as necessary to keep the animals dry and clean. Bedding material of batch no. SPAR_27/2014 (Sparconn Life Sciences Bangalore) was incorporated.
- Diet (e.g. ad libitum): A conventional laboratory pelleted diet of batch no. 400009 and 400010 from approved supplier (Nutrivet Life Sciences, Pune) was offered ad libitum.
- Water (e.g. ad libitum): Aqua guard filtered drinking water in bottles was offered ad libitum.
- Acclimation period: 5 days prior to test item administration.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.00 to 23.10 °C
- Humidity (%): 49.9 to 69.40%
- Air changes (per hr): 12 times per hour and filtered adequately
- Photoperiod (hrs dark / hrs light): 12 hours light and 12 hours dark
IN-LIFE DATES: From: To: September 11, 2014- November 17, 2014
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- NO data
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: The test item was weighed and dissolved in a vehicle to achieve desired concentration of test item. The frequency of dose preparation was daily. At the time of dosing, dose formulation was kept on the magnetic stirrer to maintain the homogeneity.
DIET PREPARATION
- Rate of preparation of diet (frequency): Daily
- Mixing appropriate amounts with (Type of food): No data available
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): Corn oil
- Concentration in vehicle: 1000 mg/Kg bw
- Amount of vehicle (if gavage): No data available
- Lot/batch no. (if required):lot nos.: MKBQ9948V and MKBG9426V
- Purity: No data available - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The active ingredient (a.i.) concentration of the test item in dose formulation were analysed by validated HPLC method on day 1 and 21. Formulation was analysed for homogeneity using two samples of each lower, middle and upper layer and found homogeneous. The mean active ingredient content at 100 mg/ml concentration of Di isopropyl adipate (CAS No. - 6938-94-9) was 97.15 and 93.52 mg/ml on day 1 and day 21, respectively.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0 or 1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- Total: 40
Main study group:
0 mg/Kg bw: 5/sex/dose
1000 mg/Kg bw: 5/sex/dose
Recovery group:
0 mg/Kg bw: 5/sex/dose
1000 mg/Kg bw: 5/sex/dose - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The limit dose level, 1000 mg/kg body weight was selected based on the information provided by Sponsor.
- Rationale for animal assignment (if not random): Random
- Rationale for selecting satellite groups: Random
- Post-exposure recovery period in satellite groups: No data available
- Section schedule rationale (if not random): No data available - Positive control:
- No data
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
- Cage side observations checked in table [No.?] were included: Mortality
DETAILED CLINICAL OBSERVATIONS: Yes
The observation period was 28 days. Animals in a recovery group scheduled for follow-up observations were kept for at least 14 days without treatment to detect delayed occurrence, or persistence of, or recovery from toxic effects.
General clinical observations of rats from the all groups were made once a day, preferably at the same time each day and considering the peak period of anticipated effects after dosing. Detailed clinical examinations were carried out once before the first treatment (to allow for within-subject comparisons) and weekly thereafter. The detailed clinical examinations were made outside the home cage, at approximately the same times, on each occasion
BODY WEIGHT: Yes
Animals were weighed during randomization, at start of treatment and thereafter weekly, till the end of experimental period. Body weight of the animals taken on the day of necropsy were used only to calculate the relative organ weight.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes, Feed consumption of all animals was determined weekly, during the treatment period.
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
- Time schedule for examinations: No data
OPHTHALMOSCOPIC EXAMINATION: Yes
Ophthalmological examination was conducted prior to exposure (During Acclimatization Period) to the test item and at the end of the dosing (main groups) and recovery periods (recovery group). Before ophthalmologic examination, mydriasis was induced using 1% tropicamide.
HAEMATOLOGY: Yes
Blood smears were prepared from the collected blood, stained with Leishman’s stain and were observed for Differential Leukocyte Count (%) and blood cell morphology.Blood smears for reticulocyte count (%) were stained by Brilliant Cresyl Blue Staining method and will be observed microscopically. Reticulocyte count were performed by observing the approximate 1000 RBCs with corresponding number of reticulocytes in different microscopic fields (under oil immersion) and were reported as percentage of the total number of RBCs observed.
CLINICAL CHEMISTRY: Yes
Blood collection of all surviving rats from the main groups and recovery groups was performed on the termination day, just prior to necropsy.
Animals were fasted overnight (approximately 16-18 hr) prior to blood collection. Blood was collected from retro orbital plexuses in vials without anticoagulant for clinical biochemistry, 4.0% Sodium EDTA for hematology and Sodium Citrate with 3.8% for coagulation factors. Clinical pathological evaluations of blood and serum was done as soon as possible, after collection.
URINALYSIS: Yes
At the last week of the treatment and recovery periods, all surviving rats of the main groups and recovery groups were housed in metabolic cages overnight, (Filtered water was provided ad libitum) and urine samples were collected. Color, appearance and volume of the urine was recorded after visual observation. The parameters including Blood/ blood cell, bilirubin, urobilinogen, ketone, protein, nitrite, glucose, pH, specific gravity leucocytes and microscopical parameters were analyzed using auto analyzer
NEUROBEHAVIOURAL EXAMINATION: Yes
Sensory reactivity to stimuli, assessment of grip strength, hind limb foot splay and motor activity assessment were conducted for rats from main groups, during the last week of treatment and that of recovery groups, in the last week of recovery period.
OTHER: Before necropsy, the oestrus cycle stage of all females was determined by taking vaginal smears. - Sacrifice and pathology:
- All surviving animals of main and recovery groups were subjected to necropsy and detailed gross pathology evaluation. Animals were fasted overnight (approximately 16-18 hr) before necropsy. Animals were weighed, sacrificed by using over dose of CO2 and examined externally. All orifices and the cranial, thoracic and visceral cavities were opened and examined macroscopically
GROSS PATHOLOGY: Yes, Organs were kept in normal saline till they are weighed. Organs were weighed as soon as possible, after they are collected. Animals moribund sacrificed and found dead during the study, organs from these animals were weighed. These included adrenals, brain (cerebrum,cerebellum,mid brain), Epididymides, Heart, Kidneys, Liver, Ovary with oviduct, Prostate and Seminal vesicle with coagulating glands, Spleen, Testes, Thymus and Uterus with Cervix.
HISTOPATHOLOGY: Yes, Full histopathology was carried out on the preserved organs and tissues of all animals in the control and limit dose group. No organ was identified as a target organ, hence no histopathology was performed in recovery group of animals. Histopathological organs included:
Adrenals
Pancreas
Aorta Peyer's Patches
Bone (femur) with joint
Pituitary
Brain (cerebrum,cerebellum,mid brain)
Prostate and Seminal vesicle with coagulating glands as a whole
Cecum Rectum
Colon Salivary glands
Duodenum Sciatic Nerve
Epididymides
Skeletal muscle
Eyes with optic nerve Skin
Spinal Cord (cervical, mid-thoracic and lumbar)
Heart
Spleen
Ileum
Sternum with marrow
Jejunum
Stomach
Kidneys
Testes
Liver
Thymus
Lung
Thyroid with Parathyroids
Mammary glands
Trachea
Mesenteric and Mandibular lymph node
Urinary Bladder
Oesophagus
Uterus with Cervix
Ovary with oviduct
Vagina - Other examinations:
- No data
- Statistics:
- Raw data was processed using statistical software Sigma Plot 11.0. The mean and standard deviation were calculated using the MS Excel or Sigma Plot 11.0 software and all data was summarized in tabular form. All continuous data (body weight, feed consumption, haematology, clinical chemistry, absolute and relative organ weights) was analysed using t-test
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Changes in kidney weight
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Clinical Observations: No clinical signs were noted at 0 and 1000 mg/kg bw
Mortality: No mortality and morbidity was observed during this study
BODY WEIGHT AND WEIGHT GAIN At 1000 mg/kg bw, no effects on body weight and body weight gain were noted during conduct of the study
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study) Feed consumption of limit dose animals was unaffected during conduct of the study, as compared to control group
FOOD EFFICIENCY No data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study) No data available
OPHTHALMOSCOPIC EXAMINATION No data available
HAEMATOLOGY Statistically significant increase in Haemoglobin count and Mean Corpuscular Haemoglobin Concentration (MCHC) were observed at the end of treatment period, as compared to control and were not dose related. Increased Neutrophil and decreased Lymphocyte count were noticed at the end of recovery period. These changes were not test item related and may due to the pre-analytical and analytical variables or incidental
CLINICAL CHEMISTRY Changes observed in Calcium, Albumin, Bile acids, Gamma-Glutamyl Transpeptidase (GGT), Triglyceride, AST and Creatinin Kinase were not dose independent
URINALYSIS Urine parameters in test groups of both the sexes were comparable with the control
NEUROBEHAVIOUR The sensory reactivity measurements recorded during this study are commonly observed in the test system and were not attributed to the test item. There was no test item related foot splay findings. Grip strength measurement of forelimbs of the main group female animals of 1000 mg/kg bw was observed statistically significant increase in forelimb grip strength of the main group female animals at 1000 mg/kg bw was observed, as compared to vehicle control. Forelimb grip strength was comparable in the recovery group of animals. No change in hind limb grip strength was noted in main and recovery group of animals. Hence, the changes observed in main group female fore limb grip strength might be incidental and not due to test item treatment. Motor activity measurements were comparable and no changes were revealed in any of the animals from all treated groups of both the sexes throughout the experimental period; except significant increased horizontal and ambulatory counts in treatment animals, as compared to control group in males. Horizontal and ambulatory counts were comparable in the recovery group of animals. Hence, the changes observed in main group male horizontal and ambulatory counts might be incidental and not due to test item treatment.
ORGAN WEIGHTS Absolute and relative organ weights were comparable in limit dose group, compared to control group. Except, increased absolute & relative weight of kidneys in males, absolute kidneys weight in females and relative organ weight of ovaries when compared to control animals. Observed changes in kidneys weight has been linked to increased functional demand such as elevation of the glomerular filtration rate and altered tubular fluid flow and not test item related adverse effect as it was below 10 % increase compared to the concurrent control.
GROSS PATHOLOGY
External Findings: Gross necropsy of all surviving male animals from all groups showed no external abnormal changes in gross observations.
Internal Findings: Gross necropsy of all surviving male and female animals from all groups showed no internal abnormal changes. Except, animal number 5 male of vehicle control group, which showed red discoloration of all lobes of lung, which could be considered as incidental change
HISTOPATHOLOGY: NON-NEOPLASTIC Tubular degeberation of kidneys and MNC infiltration in the lungs and trachea. These observed changes are inflammatory changes and are the most common observed changes in rodents. Observed tubular hypetrophy in kidney has been linked to increased functional demand such as elevation of the glomerular filtration rate and altered tubular fluid flow and not an adverse effect related to the test item. Microscopic evaluation of uterus was comparable with oestrous cycle evaluation by vaginal smear method in the main group animals
HISTOPATHOLOGY: NEOPLASTIC (if applicable)
HISTORICAL CONTROL DATA (if applicable)
OTHER FINDINGS
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No significant effects were noted at the mentioned dose level
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Mortality and Morbidity
1.1 Male
Group |
Treatment |
Dose (mg/kg bw) |
No. of Animals |
Day |
Observation |
G1 |
Vehicle control |
0 |
5 |
1-29 |
No mortality/ morbidity |
G2 |
Limit dose |
1000 |
5 |
1-29 |
No mortality/ morbidity |
G1-R |
Vehicle control -Recovery |
0 |
5 |
1-43 |
No mortality/ morbidity |
G2-R |
Limit dose - Recovery |
1000 |
5 |
1-43 |
No mortality/ morbidity |
1.2 Female
Group |
Treatment |
Dose (mg/kg bw) |
No. Of Animals |
Day |
Observation |
G1 |
Vehicle control |
0 |
5 |
1-29 |
No mortality/ morbidity |
G2 |
Limit dose |
1000 |
5 |
1-29 |
No mortality/ morbidity |
G1-R |
Vehicle control -Recovery |
0 |
5 |
1-43 |
No mortality/ morbidity |
G2-R |
Limit dose - Recovery |
1000 |
5 |
1-43 |
No mortality/ morbidity |
Table 2 Clinical Signs/ Symptoms
2.1 Male
Group |
Treatment |
Dose (mg/kg bw) |
No. Of Animals |
Day |
Clincal Sign |
Incidences |
G1 |
Vehicle control |
0 |
5 |
1-29 |
Normal |
5/5 |
G2 |
Limit dose |
1000 |
5 |
1-29 |
Normal |
5/5 |
G1-R |
Vehicle control -Recovery |
0 |
5 |
1-43 |
Normal |
5/5 |
G2-R |
Limit dose - Recovery |
1000 |
5 |
1-43 |
Normal |
5/5 |
2.2 Female
Group |
Treatment |
Dose (mg/kg bw) |
No. of Animals |
Day |
Clincal Sign |
Incidences |
G1 |
Vehicle control |
0 |
5 |
1-29 |
Normal |
5/5 |
G2 |
Limit dose |
1000 |
5 |
1-29 |
Normal |
5/5 |
G1-R |
Vehicle control -Recovery |
0 |
5 |
1-43 |
Normal |
5/5 |
G2-R |
Limit dose - Recovery |
1000 |
5 |
1-43 |
Normal |
5/5 |
Applicant's summary and conclusion
- Conclusions:
- Treatment of Wistar rats for 28 days with oral dose of 1000 mg/kg bw/day of the test chemical produced no toxicity. Findings at limit dose level of 1000 mg/kg bw/day were limited to adaptive changes in the kidneys. Hence, the No Observed Adverse Effect Level (NOAEL) of the test chemical is considered to be 1000 mg/kg/day in Wistar rats
- Executive summary:
28 days repeated dose oral toxicity study was conducted to evaluate the toxic nature of the test chemical. The study was performed using male and female Wistar rats. The animals were randomly allocated to the four groups (5/Sex/Main Group and 5/Sex/Recovery Group) and were dosed daily with a limit dose of 0 and 1000 mg/Kg bw. The test material was dissolved in corn oil to obtain the appropriate dose concentration. The animals were observed for clinical signs, mortality. Ophthalmoscopic, hematological, neurobehavioral and urinalysis was also performed in addition to gross pathological and histopathological changes. Treatment of Wistar rats for 28 days with oral dose of 1000 mg/kg bw of the test chemical produced no toxicity. Findings at limit dose level of 1000 mg/kg bw were limited to adaptive changes in the kidneys. Hence, the No Observed Adverse Effect Level (NOAEL) of the test chemical is considered to be 1000 mg/kg/day in Wistar rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)